Emerging treatment options for short bowel syndrome: potential role of teduglutide
Authors:
Open Access
- 1 August 2011
- journal article
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. 4, 189-96
Abstract
Peer reviewed article authored by (Tee CT, Wallis K, Gabe SM). Read article or submit your manuscript for publishing.Keywords
This publication has 45 references indexed in Scilit:
- The “cryptic” mechanism of action of glucagon-like peptide-2American Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle FunctionGastroenterology Research and Practice, 2009
- Glucagon-like Peptide-2 Does Not Modify the Growth or Survival of Murine or Human Intestinal Tumor CellsCancer Research, 2008
- Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblastsEuropean Journal of Pharmacology, 2008
- GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptorsRegulatory Peptides, 2005
- Glucagon-like peptide-2: Divergent signaling pathways1Journal of Surgical Research, 2004
- Effect of glutamine in short-bowel syndromeClinical Nutrition, 2001
- Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled studyGut, 2000
- GLP-2 augments the adaptive response to massive intestinal resection in ratAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1998
- Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome: A randomized, controlled studyGastroenterology, 1997